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During the last decade, dendritic cells (DCs) have come
to be appreciated as critical controllers of the immune
response, especially T cell responses. Although T lymphocytes actually mediate resistance to infections,
transplants, and even tumors, without proper instruction
from DCs, T cells would be severely compromised. DCs
convert antigens from foreign cells and infectious microorganisms into short peptides that are bound to membrane proteins of the major histocompatibility complex
(MHC). These MHC–peptide complexes are formed intracellularly but are ultimately presented on the plasma
membrane where they serve as ligands for antigen-specific T cell receptors (TCR). In addition to TCR ligand
formation, DCs carry out many other functions, some
to be considered below, which allow them to control
immunity at several points.
Despite their importance, the DC can be regarded as
the Cinderella of the immune system, for years kept by
the hearths of a few laboratories. With added attention,
as illustrated by two papers by Geijtenbeek and colleagues in this issue of Cell, one can begin to appreciate
some of the DC’s glamor. Both papers center on DCSIGN, a new DC-restricted molecule. DC-SIGN in turn
qualifies as Cinderella’s glass slipper, as it seems to be
used by the dashing T cell and the wicked HIV-1 to
identify their DC. Yet the slipper, like its wearer, had to
be rescued from years of oblivion. None of the new
ideas described in the papers by Geijtenbeek et al. were
apparent from the genomic sequence of DC-SIGN, first
reported in 1992 and since then deposited several times
in gene banks. Instead the research had to shift to DCs
for the importance of this molecule to be appreciated.
DC SIGN is a type II membrane protein with an external
mannose-binding, C-type lectin domain. It was cloned
from a placental library, through its capacity to bind the
glycan-rich HIV-1 envelope in the absence of CD4 (Curtis
et al., 1992), the classic virus receptor. In the first of
these two papers (Geijtenbeek et al., 2000a), the lectin
is rediscovered and renamed DC-SIGN, because it is a
“DC-specific, ICAM-3 grabbing, nonintegrin.” It is proposed that the interaction of DC-SIGN with ICAM-3 establishes the initial contact of the DC with a resting T cell,
helping to explain the potency with which DCs initiate T
cell immunity. Potency has long been apparent in tissue
culture and in experimental animals, and this adjuvant
role of DCs has been extended to humans (Dhodapkar
and Bhardwaj, 2000). The second paper (Geijtenbeek et
al., 2000b) addresses the known capacity of DCs to
promote HIV-1 infection in culture. DC-SIGN proves to
be a special kind of viral receptor, promoting binding
and transmission of HIV-1 to T cells, rather than viral
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entry into the DC. Therefore, DC-SIGN likely will be pivotal for explaining some important functions of DCs.
The Potency of DC in Initiating Immune Responses
from Resting T Cells
The term “potency” indicates that relatively small numbers of DCs, and relatively low doses of an antigen or
other T cell stimulus, are sufficient to initiate rapid and
strong responses, such as T cell proliferation and lymphokine production. Potency is not simply a matter of
more efficient MHC–peptide complex formation, although this too is a newly recognized mechanism used
by DCs to control immunity (Inaba et al., 2000). Instead
potency is readily observed with stimuli that do not require processing, e.g., polyclonal mitogens, microbial
superantigens, and transplantation antigens. DCs are
also effective when the amount of membrane-bound
TCR ligand is vanishingly small, as few as 100–1000
ligands on the entire cell surface (Bhardwaj et al., 1993).
For these reasons, the efficacy of DCs has been attributed to special accessory molecules. Many such molecules are found on DCs, e.g., CD48, -54, -58, -80, -86,
and the corresponding antibodies can block DC–T cell
interactions. However, these membrane proteins are
shared with other antigen-presenting cells. DC-SIGN is
the first recognized DC-restricted product that helps
stimulate resting T cells.
The Figdor lab realized that resting T cells expressed
the adhesion molecule ICAM-3. In contrast to what was
expected, ICAM-3 did not bind to ␤2 integrins on DCs.
When they made antibodies to block ICAM-3 binding to
DCs, the monoclonals identified a small 44 kDa molecule. Its binding to ICAM-3 was Ca2⫹ dependent and
blocked by mannan. The antibodies reacted specifically
with DCs. Cloning showed that the ICAM-3-binding molecule was identical to the previously defined HIV-1 envelope–binding lectin (Curtis et al., 1992). In functional
tests, the renamed DC-SIGN contributed to transient
DC–T cell clustering and responses to transplantation
antigens.
Geijtenbeek et al. (2000a) propose that DC-SIGN mediates the known loose adhesion that takes place between DCs and T cells in the apparent absence of foreign
antigen (Figure 1). Such adhesion seems necessary,
because MHC–peptide ligands are membrane bound,
typically scarce (10–1000 copies/cell), and need to be
recognized by the TCR, another membrane molecule.
DC-SIGN-mediated adhesion provides an opportunity
for the TCR to scan the DC surface to identify these
small amounts of TCR ligand, which then activate the
resting T cell. Subsequently T cells respond vigorously
to antigens presented by other cells, but by then, the
activated T cells are replete with their own functional
adhesion molecules.
Further experiments will decipher this proposed
mechanism of action and dissect DC-SIGN function in
vivo. Mice deleted of the gene for DC-SIGN will be valuable, assuming there are no additional homologs. Nevertheless, it is impressive at this early stage of research
to recall that human cells have been used to uncover
most of the important accessory membrane proteins
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Figure 1. A Proposed Sequence of Action for the Initiation of Immunity by DCs

that control T cell function, not just DC-SIGN and ICAM-3.
These include CD58 (LFA-3) for CD2; CD54 (ICAM-1) for
CD11a (LFA-1); CD40L (gp39) for CD40; CD80 (B7-1) and
CD86 (B7-2) for CD28 and CD154 (CTLA-4) (Figure 1).
Geijtenbeek et al. (2000a) detected DC-SIGN on DCs
that were not mature or terminally differentiated, and
expression of DC-SIGN did not increase when the DCs
matured. This raises the possibility that DC-SIGN is
mainly needed by developing DCs, not yet expressing
optimal levels of MHC–peptide and accessory molecules like CD86, to contact ICAM-3 on resting T cells
and then mature with help from the responding T cells.
Conceivably, DC-SIGN could be involved in T cell responses other than classical immunity, such as the induction of tolerance and immune regulation.
Although DC-SIGN could be a long-sought, DCunique molecule for T cell adhesion, and thereby help
to explain the potency of DCs, there has been progress
on another hypothesis. DCs are held to have other
unique products to enhance signaling together with the
TCR, i.e., costimulation. While DCs are remarkable in
this regard, to date costimulation is not known to involve
a DC-specific product. Instead, the potent costimulator,
CD86, is abundant on DCs relative to other antigenpresenting cells. More remarkably, during the vesicular
transport of newly formed MHC–peptide complexes in
developing DCs, the complexes move together with
CD86. Upon arrival at the DC surface, MHC–peptide
and CD86 are deposited as stable clusters (Inaba et
al., 2000). Therefore DCs are designed to set up the
“immunological synapse.”
The concept of a synapse, a term first coined by William Paul, proposes a central contact zone in which the
APC and T cell membranes are only 134 Å apart (Davis
and van der Merwe, 1996; Shaw and Dustin, 1997). The
zone contains multiple copies of molecular couples that
span this distance, e.g., CD48 or -58 plus CD2, CD80

or -86 plus CD28, and importantly, MHC–peptide plus
TCR (Figure 1). This assembly of supramolecular aggregates may facilitate costimulation and sustain the low
affinity interaction between TCR ligands and the TCR.
Direct experiments on synapses have so far used activated T cells. DCs might allow the concept to be pursued
in naive T cells. In sum, more precise mechanisms are
beginning to explain DC function: DC-SIGN for T cell
adhesion, and preformed aggregates of MHC–peptide
and membrane accessories for costimulation.
We have only been discussing the basis for DC potency in vitro. In vivo, DCs are found in peripheral tissues,
such as the skin and airways but they can migrate to
lymphoid tissues. There, in the T cell areas, the DCs are
in full view of the circulating, naive lymphocyte repertoire
and can even make chemokines that attract these T
cells (Adema et al., 1997). The match of the DC and T
cell can then be made via DC-SIGN, allowing the intimate
cross-talk between the two cells to begin (Ingulli et al.,
1997). Nonetheless, to control immunity, the DC displays
other functions prior to the use of DC-SIGN. In the peripheral outposts for antigen entry, DCs are immature
requiring a stimulus, such as exposure to microbial
products or inflammatory cytokines, for terminal differentiation (Cella et al., 1997). The immature DCs express
several receptors for antigen uptake, including other
lectins (Figure 1, top). The endocytic system is in turn
regulated by a maturation stimulus to efficiently convert
antigens to MHC–peptide complexes, in concert with
CD86 costimulators as mentioned above (Inaba et al.,
2000). DC migration from the periphery to the lymphoid
tissues involves mobilization via multidrug resistance
receptors (Randolph et al., 1998) and chemotaxis through
the CCR7 receptor toward chemokines produced in
lymphoid tissues and lymphatic channels (Forster et al.,
1999). After DC-SIGN functions, the synapse forms and
the resting T cell is activated. Then TNF family members
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Figure 2. Proposed Pathways for the Transmission of HIV-1 or SIV to Permissive T Cells
The upper, DC-SIGN-dependent pathway
does not distinguish M-tropic from T-tropic
HIV-1. It may operate, for example, on DCs
beneath mucosal epithelial surfaces and is
the major pathway in the cells studied by Geijtenbeek et al. (2000b). The lower, infectiondependent pathway may pertain to DCs
within mucosal epithelia. Both pathways also
could operate in acute and chronic phases
of infection in lymphoid tissues.

on the T cell, like CD40L and TRANCE, prolong DC survival and cytokine production (Josien et al., 2000), especially the IL-12 needed for strong T cell–mediated immunity (Figure 1). Therefore DC potency is not due to one
surface or secreted molecule. It results from many welltimed and spatially organized specializations.
DCs and the Transmission of HIV-1
The second of the two papers (Geijtenbeek et al., 2000b)
reveals a new way for HIV-1 to exploit the DC. The
investigators describe a fascinating DC-SIGN-dependent mechanism. This lectin can capture HIV-1 at low
external titres. Without allowing viral entry, DC-SIGN
retains the attached virus in an infectious state for days
and then transmits it to replication-permissive T cells.
The in vitro data are fortified with micrographs of tissue
sections. DC-SIGN is found on dendritic profiles beneath genital epithelium, a major potential site for HIV-1
transmission, and in the T cell areas, the sites for viral
replication especially in acute infection. This pure delivery role for DC-SIGN is consistent with data that, in
lymphoid tissues, HIV-1 and SIV mainly replicate in CD4⫹
T cells, not DCs (Stahl-Hennig et al., 1999).
The new experiments use a standard system to study
the involvement of DCs in HIV-1 transmission (Pope et
al., 1994). The model is to add HIV-1 to cultured DCs
for 1–2 hr, wash, and at varying times, add in T cells
and follow the levels and cellular sites of viral replication.
A vigorous infection occurs, primarily in T cells. In such
a model, antibodies to DC-SIGN exerted a significant
but sometimes incomplete block of transmission. When
transfected cells were used to pursue the relative roles
of DC-SIGN and more classical HIV-1 receptors, DCSIGN was not an entry receptor and did not influence
the entry role of CD4 and CCR5. However, DC-SIGN on
one transfectant captured virus, even when present in
small amounts, and transmitted the HIV-1 to CD4 and
CCR5 on other cells (Figure 2, top). DC-SIGN literally
“presents” HIV-1 to T cells, but in a nonprocessed infectious form.

It is possible that other pathogens are also transmitted
via DCs and in particular via DC-SIGN. The glycan ligands for this lectin could be present on other viral
envelopes, the cell walls of other microbes, or even
tumor cells. Also, because DC-SIGN retains its HIV-1
ligand in a native state, this and other lectins could
present vaccines to protective B cells, which must react
to native antigens. If the vaccine were simultaneously
processed and presented to helper T cells, DC-SIGN
would even set up an effective DC–T–B “ménage à trois,”
capable of inducing strong immunity, including mucosal
immunity (Fayette et al., 1997).
DC-SIGN is not the only attraction that HIV-1 finds in
DCs. The virus can infect certain DCs in culture (Figure
2, bottom, red arrows). HIV-1 is capable of replication
in immature DCs, and possibly mature DCs that are
interacting with CD40L or T cells (Granelli-Piperno et
al., 1999). So while DC-SIGN can transport HIV-1 and
enhance infection of T cells, locally or in lymphoid tissues, direct infection could also amplify the amount of
virus that DCs deliver. Both pathways (Figure 2) may
enhance the overall pathogenesis of HIV-1 infection,
although Geijtenbeek et al. (2000b) observe that DCSIGN in their cells plays the major role in viral replication,
especially at low doses of HIV-1.
Importantly, it is well established that M-tropic strains
of HIV-1 are preferentially transmitted among humans.
One possible explanation is that selection takes place
at the level of DC infection. By contrast, DC-SIGN ferries
both M- and T-tropic viruses to T cells. Geijtenbeek et
al. (2000b) did not detect DC-SIGN on DCs (Langerhans
cells) within the genital epithelium, only on DCs beneath
the surface. These two subsets of DCs, termed “epidermal or epithelial” and “dermal or subepithelial,” represent distinct pathways of differentiation (Caux et al.,
1996). Since epidermal, DC-SIGN-negative DCs likely
select for M-tropic HIV-1 (Reece et al., 1998), these DCs
in vivo may account for the selective transmission of
M-tropic HIV-1, which then binds to additional subepithelial, DC-SIGN-positive DCs, greatly amplifying delivery
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of virus to T cells locally and eventually lymphoid tissue.
Beyond these functions in HIV-1 capture and conveyance, DCs can serve another nefarious role, activating
T cells to be permissive for HIV-1 replication (Figure 2,
right).
Implications
A new DC-restricted molecule, DC-SIGN, demystifies
two of this cell’s contrasting functions: stimulating T
lymphocytes to develop immunity, and enhancing HIV-1
and SIV replication. For immunity, it is implied that DCSIGN allows the DC to interact temporarily with naive T
cells. Critical events of antigen recognition can then
ensue, leading to the formation and function of a contact
zone termed the immunological synapse, rich in interacting adhesion and signaling molecules. For immunodeficiency viruses, DC-SIGN enables the DC to bind and
transmit virus to permissive T cells. This should occur
in vivo beneath the genital epithelium and in the T cell
areas of lymphoid tissues, because of DC-SIGN expression in these sites. DC-SIGN may allow DCs to carry
additional pathogens to their cellular targets. The new
data identify DC-SIGN as a potential site on DCs for
manipulating both the immune response and HIV-1 infection. The results illustrate a larger issue. To understand and manipulate immune responsiveness, and
many clinical areas involving the immune system, one
should not restrict the analysis to antigens and lymphocytes. One must also consider DCs, the captivating controllers of immunity.
Acknowledgments
The author regrets that, because of space limitations, many valuable
references could not be included.
Selected Reading
Adema, G.J., Hartgers, F., Verstraten, R., de Vries, E., Marland, G.,
Menon, S., Foster, J., Xu, Y., Nooyen, P., McClanahan, T., Bacon,
K.B., and Figdor, C.G. (1997). Nature 387, 713–717.
Bhardwaj, N., Young, J.W., Nisanian, A.J., Baggers, J., and
Steinman, R.M. (1993). J. Exp. Med. 178, 633–642.
Caux, C., Vanbervliet, B., Massacrier, C., Dezutter-Dambuyant, C.,
de Saint-Vis, B., Jacquet, C., Yoneda, K., Imamura, S., Schmitt, D.,
and Banchereau, J. (1996). J. Exp. Med. 184, 695–706.
Cella, M., Sallusto, F., and Lanzavecchia, A. (1997). Curr. Opin. Immunol. 9, 10–16.
Curtis, B.M., Scharnowske, S., and Watson, A.J. (1992). Proc. Natl.
Acad. Sci. USA 89, 8356–8360.
Davis, S.J., and van der Merwe, P.A. (1996). Immunol. Today 17,
177–187.
Dhodapkar, M.V., and Bhardwaj, N. (2000). J. Clin. Immunol., in press.
Fayette, J., Dubois, B., Vandenabelle, S., Bridon, J.-M., Vanbervliet,
B., Durand, I., Banchereau, J., Caux, C., and Briere, F. (1997). J.
Exp. Med. 185, 1909–1918.
Forster, R., Schubel, A., Breitfeld, D., Kremmer, E., Renner-Muller,
I., Wolf, E., and Lipp, M. (1999). Cell 99, 23–33.
Geijtenbeek, T.B.H., Torensma, R., van Vliet, S.J., van Duijnhoven,
G.C.F., Adema, G.J., van Kooyk, Y., and Figdor, C.G. (2000a). Cell
100, this issue, 575–585.
Geijtenbeek, T.B.H., Kwon, D.S., Torensma, R., van Vliet, S.J., van
Duijnhoven, G.C.F., Middel, J., Cornelissen, I.L.M.H.A., Nottet,
H.S.L.M., KewalRamani, V.N., Littman, D.R., Figdor, C.G., and van
Kooyk, Y. (2000b). Cell 100, this issue, 587–597.
Granelli-Piperno, A., Finkel, V., Delgado, E., and Steinman, R.M.
(1999). Current Biol. 9, 21–29.

Inaba, K., Turley, S., Iyoda, T., Yamaide, F., Shimoyama, S., Reis e
Sousa, C., Germain, R.N., Mellman, I., and Steinman, R.M. (2000).
J. Exp. Med., in press.
Ingulli, E., Mondino, A., Khoruts, A., and Jenkins, M.K. (1997). J.
Exp. Med. 185, 2133–2141.
Josien, R., Hi, H.-L., Ingulli, E., Sarma, S., Wong, B.R., Vologodskaia,
M., Steinman, R.M., and Choi, Y. (2000). J. Exp. Med. 191, 495–501.
Pope, M., Betjes, M.G.H., Romani, N., Hirmand, H., Cameron, P.U.,
Hoffman, L., Gezelter, S., Schuler, G., and Steinman, R.M. (1994).
Cell 78, 389–398.
Randolph, G.J., Beaulieu, S., Pope, M., Sugawara, I., Hoffman, L.,
Steinman, R., and Muller, W.A. (1998). Proc. Natl. Acad. Sci. USA
95, 6924–6929.
Reece, J.C., Handley, A., Anstee, J., Morrison, W., Crowe, S.M., and
Cameron, P.U. (1998). J. Exp. Med. 187, 1623–1631.
Shaw, A.S., and Dustin, M.L. (1997). Immunity 6, 361–369.
Stahl-Hennig, C., Steinman, R.M., Tenner-Racz, K., Pope, M., Stolte,
N., Matz-Rensing, K., Grobschupff, G., Raschdorff, B., Hunsmann,
G., and Racz, P. (1999). Science 285, 1261–1265.

